AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Ocular Therapeutix, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0FT93
6.50▼ 0.11 (-1.66%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
6.61
Day's Range
6.35 – 6.68
52-Week Range
6.00 – 16.44
Volume
1.9M
Avg Volume
3.6M
Share Statistics
Shares Outstanding
Employees
325
Exchange
XNAS
Listed
2014-07-25
Share count as of July 31, 2026

Ocular Therapeutix, Inc. (OCUL) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Ocular Therapeutix, Inc. (OCUL)
What is Ocular Therapeutix, Inc.'s Market Cap?
Ocular Therapeutix, Inc.'s Market Cap is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s Enterprise Value?
Ocular Therapeutix, Inc.'s Enterprise Value is $828.9M, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s Price / Sales?
Ocular Therapeutix, Inc.'s Price / Sales is 27.4×, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s EV / Revenue?
Ocular Therapeutix, Inc.'s EV / Revenue is 15.9×, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s EV / EBITDA?
Ocular Therapeutix, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s Revenue (TTM)?
Ocular Therapeutix, Inc.'s Revenue (TTM) is $52.1M, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s Net Income (TTM)?
Ocular Therapeutix, Inc.'s Net Income (TTM) is -$301.4M, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s EBITDA?
Ocular Therapeutix, Inc.'s EBITDA is -$308.5M, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s Diluted EPS (TTM)?
Ocular Therapeutix, Inc.'s Diluted EPS (TTM) is -1.37, based on as-reported figures from SEC (XBRL) filings.
What is Ocular Therapeutix, Inc.'s EBITDA Margin?
Ocular Therapeutix, Inc.'s EBITDA Margin is -592.6%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · OCULAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue, net—
YoY growth+0.1%—-22.4%-5.7%
Costs and operating expenses:
Cost of product revenue—
Research and development—
Selling and marketing—
General and administrative—
Total costs and operating expenses—
% of revenue709.3%—626.5%572.3%
Loss from operations—
% of revenue-609.3%—-526.5%-472.3%
Other income (expense):
Interest income—
Interest expense—
Change in fair value of derivative liabilities—
Gain on sale of property and equipment———
Total other income (expense), net—
Net loss
% of revenue-584.5%—-488.0%-477.3%
Net loss per share, basic (in dollars per share)—
Net loss per share, diluted (in dollars per share)——